Drug Response Dx Closes First Round of Financing

Published On January 8, 2013 |

Drug Response Dx, a Hennigsdorf, Germany-based developer of proprietary RA biomarkers based on technology licensed from Max-Planck-Innovation, closed itd first round of financing.

Backers included QIAGEN and High-Tech Gründerfonds.

Founded in February 2012 by Dr. Zoltán Konthur, Dr. Jörg-M. Hollidt, Dr. Karl Skriner and Dr. Joachim Rautter, Drug Response Dx aims to predict efficacy of TNF-alpha inhibitors in rheumatoid arthritis patients.

The company intends to use the capital, whose amount was not disclosed, to advance its biomarker test kit for rheumatoid arthritis treatment. A proof of concept is already in place for the antibody-based verification procedure in an ELISA format (Enzyme Linked Immunosorbent Assay). The required biomarkers can also already be produced in high technical quality and fairly large quantities.



Like this Article? Share it!

Leave a Reply